PHERGain随机II期试验5年二次分析:HER2阳性早期乳腺癌化疗降阶梯结局与ctDNA探索结果
5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial
Nature Medicine 在线发表 PHERGain 随机II期试验的5年二次分析,报告HER2阳性早期乳腺癌化疗降阶梯的长期结局,并给出循环肿瘤DNA(ctDNA)探索性分析结果。作者认为该结果支持以PET引导的自适应策略用于治疗降阶梯的临床实用性,ctDNA分析结果或有助于指导后续治疗思路。
PHERGain的5年二次分析给出PET引导降阶梯的长期随访数据,并附ctDNA探索结果,可供对照该策略的随访结局。
Nature Medicine, Published online: 29 October 2026; doi:10.1038/s41591-026-04723-w
A 5-year secondary analysis of the phase 2 PHERGain trial supports the clinical utility of a PET-guided adaptive strategy for treatment de-escalation in HER2-positive early breast cancer and provides circulating tumor DNA insights that could inform further treatment approaches.
来源:Nature Medicine · nature.com